VUKE 📈 Vanguard FTSE 100 UCITS CHF - Overview

Exchange: SW • Country: Switzerland • Currency: CHF • Type: Etf • ISIN: IE00B810Q511 • UK Large-Cap Equity

VUKE: Stocks, Equities, UK, Companies

The Vanguard FTSE 100 UCITS ETF CHF, traded under the ticker VUKE on the Swiss exchange, is a financial instrument designed to track the performance of the UK's largest companies. It's part of the Vanguard family, a well-established global investment management company with a website at http://global.vanguard.com. This ETF is domiciled in Ireland, which provides a favorable regulatory environment for investment funds.

At its core, the Vanguard FTSE 100 UCITS ETF CHF aims to replicate the performance of the Morningstar UK All Cap TME NR GBP index, identified by the ISIN code IE00B810Q511. This index is a broad market benchmark that captures the overall performance of the UK equity market, including large, mid, and small-cap stocks. By tracking this index, the ETF offers investors exposure to the UK's diverse economy, including sectors like finance, healthcare, consumer goods, and more.

As an ETF, or exchange-traded fund, the Vanguard FTSE 100 UCITS ETF CHF combines the benefits of index funds with the trading flexibility of individual stocks. It's categorized under UK Large-Cap Equity, meaning it primarily invests in the largest and most established companies listed on UK stock exchanges. This category of ETFs is often sought after by investors looking for a stable, long-term investment with potential for growth, as large-cap companies tend to be less volatile than their smaller counterparts.

Investing in the Vanguard FTSE 100 UCITS ETF CHF can provide diversification benefits to a portfolio, especially for those looking to gain exposure to the UK market. Since it's denominated in Swiss Francs (CHF), it may also appeal to investors who prefer to hold their investments in this currency, potentially reducing currency risk for those whose base currency is the CHF. Like other ETFs, it's traded on an exchange, allowing investors to buy and sell units throughout the trading day, which can be advantageous for those looking to quickly adjust their portfolios in response to market movements.

Additional Sources for VUKE ETF

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

VUKE ETF Overview

Market Cap in USD 3,969m
Category UK Large-Cap Equity
TER 0.10%
IPO / Inception 2012-05-22

VUKE ETF Ratings

Growth 5y 40.1%
Fundamental -
Dividend 50.3%
Rel. Strength Industry 212
Analysts -
Fair Price Momentum 39.18 CHF
Fair Price DCF -

VUKE Dividends

Dividend Yield 12m 3.15%
Yield on Cost 5y 3.58%
Annual Growth 5y 4.39%
Payout Consistency 90.8%

VUKE Growth Ratios

Growth Correlation 3m 11.3%
Growth Correlation 12m 81.5%
Growth Correlation 5y 76%
CAGR 5y 3.42%
CAGR/Mean DD 5y 0.37
Sharpe Ratio 12m 0.78
Alpha -1.77
Beta 0.60
Volatility 20.34%
Current Volume 0.9k
Average Volume 20d 2.6k
What is the price of VUKE stocks?
As of January 03, 2025, the stock is trading at CHF 40.08 with a total of 909 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -1.09%, over three months by -0.51% and over the past year by +15.97%.
Is Vanguard FTSE 100 UCITS CHF a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Vanguard FTSE 100 UCITS CHF (SW:VUKE) is currently (January 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 40.08 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of VUKE as of January 2025 is 39.18. This means that VUKE is currently overvalued and has a potential downside of -2.25%.
Is VUKE a buy, sell or hold?
Vanguard FTSE 100 UCITS CHF has no consensus analysts rating.
What are the forecast for VUKE stock price target?
According to ValueRays Forecast Model, VUKE Vanguard FTSE 100 UCITS CHF will be worth about 43 in January 2026. The stock is currently trading at 40.08. This means that the stock has a potential upside of +7.34%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 43 7.3%